keyword
MENU ▼
Read by QxMD icon Read
search

crpc liver metastasis treatment

keyword
https://www.readbyqxmd.com/read/27762505/use-of-5-fluorouracil-loaded-micelles-and-cisplatin-in-thermosensitive-chitosan-hydrogel-as-an-efficient-therapy-against-colorectal-peritoneal-carcinomatosis
#1
Qin Yun, Si Song Wang, Shan Xu, Jin Ping Yang, Juan Fan, Ling Lin Yang, Yue Chen, Shao Zhi Fu, Jing Bo Wu
Colorectal peritoneal carcinomatosis (CRPC) is a common systemic metastasis of intra-abdominal cancers. Intraperitoneal chemotherapy against CRPC is at present the preferred treatment. The aim of this study is to develop a novel hydrogel drug delivery system through the combination of 5-fluorouracil (5-FU) loaded polymeric micelles and cisplatin (DDP) in biodegradable thermosensitive chitosan (CS) hydrogel. The prepared CS hydrogel drug is a free-flowing solution at room temperature and forms a stationary gel at body temperature...
October 20, 2016: Macromolecular Bioscience
https://www.readbyqxmd.com/read/26883015/prognostic-value-of-a-computer-aided-diagnosis-system-involving-bone-scans-among-men-treated-with-docetaxel-for-metastatic-castration-resistant-prostate-cancer
#2
Koichi Uemura, Yasuhide Miyoshi, Takashi Kawahara, Shuko Yoneyama, Yusuke Hattori, Jun-ichi Teranishi, Keiichi Kondo, Masatoshi Moriyama, Shigeo Takebayashi, Yumiko Yokomizo, Masahiro Yao, Hiroji Uemura, Kazumi Noguchi
BACKGROUND: The bone scan index (BSI), which is obtained using a computer-aided bone scan evaluation system, is anticipated to become an objective and quantitative clinical tool for evaluating bone metastases in prostate cancer. Here, we assessed the usefulness of the BSI as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated using docetaxel. METHODS: We analyzed 41 patients who received docetaxel for mCRPC. The Bonenavi system was used as the calculation program for the BSI...
2016: BMC Cancer
https://www.readbyqxmd.com/read/26256961/prognostic-impacts-of-metastatic-site-and-pain-on-progression-to-castrate-resistance-and-mortality-in-patients-with-metastatic-prostate-cancer
#3
Kyo Chul Koo, Sang Un Park, Ki Hong Kim, Koon Ho Rha, Sung Joon Hong, Seung Choul Yang, Byung Ha Chung
PURPOSE: To investigate predictors of progression to castration-resistant prostate cancer (CRPC) and cancer-specific mortality (CSM) in patients with metastatic prostate cancer (mPCa). MATERIALS AND METHODS: A retrospective analysis was performed on 440 consecutive treatment-naïve patients initially diagnosed with mPCa between August 2000 and June 2012. Patient age, body mass index (BMI), Gleason score, prostate-specific antigen (PSA), PSA nadir, American Joint Committee on Cancer stage, Visual Analogue Scale pain score, Eastern Cooperative Oncology Group performance score (ECOG PS), PSA response to hormone therapy, and metastatic sites were assessed...
September 2015: Yonsei Medical Journal
https://www.readbyqxmd.com/read/25936418/pharmacokinetics-pharmacodynamics-and-clinical-efficacy-of-abiraterone-acetate-for-treating-metastatic-castration-resistant-prostate-cancer
#4
REVIEW
Christopher Sejong Han, Rutveej Patel, Isaac Yi Kim
INTRODUCTION: Androgen signaling axis (ASA) continues to play a crucial role in castration-resistant prostate cancer (CRPC). One of the proposed mechanisms is the activation of ASA by adrenal and intratumoral androgens. Targeted therapy to deplete such androgen sources should be effective in treating men with CRPC. AREAS COVERED: Abiraterone acetate (AA) is a selective irreversible inhibitor of CYP 17. It is orally administered and is converted to its active metabolite abiraterone by the liver...
June 2015: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/23299520/is-there-a-possibility-of-a-cure-in-patients-with-colorectal-peritoneal-carcinomatosis-amenable-to-complete-cytoreductive-surgery-and-intraperitoneal-chemotherapy
#5
Diane Goéré, David Malka, Dimitri Tzanis, Vinicius Gava, Valérie Boige, Clarisse Eveno, Léon Maggiori, Frédéric Dumont, Michel Ducreux, Dominique Elias
BACKGROUND: Although a randomized trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) over systemic chemotherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer (CRPC) is still a matter of debate. The aims of this study were to evaluate long-term outcome after CRS and IPC and to identify the prognostic factors associated with a cure. METHODS: Patients were considered cured if the disease-free survival interval lasted at least 5 years after the treatment of CRPC or its last recurrence...
June 2013: Annals of Surgery
https://www.readbyqxmd.com/read/20499131/a-phase-ii-study-of-2-methoxyestradiol-2me2-nanocrystal%C3%A2-dispersion-ncd-in-patients-with-taxane-refractory-metastatic-castrate-resistant-prostate-cancer-crpc
#6
Michael R Harrison, Noah M Hahn, Roberto Pili, William K Oh, Hans Hammers, Christopher Sweeney, Kyungmann Kim, Scott Perlman, Jamie Arnott, Carolyn Sidor, George Wilding, Glenn Liu
PURPOSE: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC. EXPERIMENTAL DESIGN: Patients with metastatic CRPC who had progressed on only one prior taxane-based regimen were eligible. All patients received 2ME2 NCD at 1,500 mg orally four times daily, repeated in 28 day cycles...
December 2011: Investigational New Drugs
https://www.readbyqxmd.com/read/19697395/comparison-of-optimally-resected-hepatectomy-and-peritonectomy-patients-with-colorectal-cancer-metastasis
#7
COMPARATIVE STUDY
Christopher Q Cao, Tristan D Yan, Winston Liauw, David L Morris
BACKGROUND: Hepatectomy is the standard of care for patients with colorectal liver metastases (CRLM) but cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) are still not widely accepted as the definitive treatment for patients with peritoneal carcinomatosis of colorectal origin (CRPC). We analyzed our data to compare survival outcomes for patients in these two groups who achieved optimal resection. METHODS: We examined our prospectively collected database for CRLM and CRPC patients who underwent hepatectomy or peritonectomy from 1995 to 2008...
December 1, 2009: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/19434455/a-systematic-review-and-meta-analysis-of-cytoreductive-surgery-with-perioperative-intraperitoneal-chemotherapy-for-peritoneal-carcinomatosis-of-colorectal-origin
#8
REVIEW
Christopher Cao, Tristan D Yan, Deborah Black, David L Morris
BACKGROUND: The objective of the present meta-analysis was to analyze the survival outcomes of patients with colorectal peritoneal carcinomatosis (CRPC), with particular focus on cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC). METHODS: A search was conducted on Medline from 1950 to February 2009 and Pubmed from 1950 to February 2009 for original studies on CRS with PIC. All articles included in this study were assessed with the application of predetermined selection criteria...
August 2009: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/18789732/safety-and-efficacy-of-sorafenib-in-patients-with-castrate-resistant-prostate-cancer-a-phase-ii-study
#9
Mohammad Reza Safarinejad
PURPOSE: We determined the safety and efficacy of sorafenib in patients with castrate resistant prostate cancer (CRPC). METHODS: Sixty-four chemotherapy and radiotherapy naïve patients with CRPC received 400 mg sorafenib orally twice daily in 6-week cycles. All patients had bone metastasis, while 16 had lymph node-, 9 had liver-, and 10 had lung metastases. Treatment was continued until disease progression or excessive toxicity. RESULTS: All patients were assessable for response...
January 2010: Urologic Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"